Profiling Active B-cell Clones in Cerebral Spinal Fluid and Serum

Technology #2015-064

Questions about this technology? Ask a Technology Manager

Download Printable PDF

David L. Murray M.D., Ph.D.
David R. Barnidge Ph.D.
Managed By
Reeghan W. Raffals J.D.
Patent Protection
US Patent Pending
US Patent Pending
US Patent Pending

High mass accuracy is used to measure Igs in CSF and serum. The mass accuracy allows for direct quantitation of each kappa and lambda light chain and can be used as a surrogate marker for active clonal B-cells. This method increases the accuracy of clone matching between serum and CSFand utilizes top-down mass spectrometry which allow for fragmentation patterns to be used for absolute identification. In addition, this method can directly quantitate each CSF clone. This method allows for physicians to monitor response and effectiveness of treatments. Lastly, the method has lower supply costs in comparison to IFE.

The results of this test help support the diagnosis of many diseases including multiple sclerosis, neuromyelitis optica, neurosarcoidosis,subacute sclerosisng panecephhalitis and Guillian-Barre Syndrome.